OpenAlex
PricingAboutJobs
Log inGet started
Work

Programmed death ligand-1 (PD-L1) as a predictive marker for immunotherapy in solid tumours: a guide to immunohistochemistry implementation and interpretation

HTML

Year: 2020
Type: review
Source: Pathology
DOI: 10.1016/j.pathol.2020.10.007
Authors: Elizabeth C. Paver, Wendy A. Cooper, Andrew J. Colebatch, Peter M. Ferguson, Sean K. Hill, Trina Lum, Joo-Shik Shin, Sandra O'Toole, Lyndal Anderson, Richard A. Scolyer, Ruta Gupta
Institutions: Royal Prince Alfred Hospital, NSW Health Pathology, The University of Sydney, Western Sydney University, Melanoma Institute Australia, Gold Coast Hospital
Language: English

Topic: Cancer Immunotherapy and Biomarkers
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Keywords: PD-L1, PD-1/PD-L1 inhibitors, predictive biomarkers, immunotherapy response prediction, PD-L1 immunohistochemistry, solid tumors, assay validation, grading criteria, quality assurance, non-small cell lung cancer, melanoma, head and neck cancer, triple-negative breast cancer, renal cell carcinoma, urothelial carcinoma, colorectal cancer, hepatocellular carcinoma, endometrial cancer
SDG: Good health and well-being

Open Access status: closed

Funders: Amgen, Bristol-Myers Squibb, GlaxoSmithKline, Novartis, Myriad Genetics, Qbiotics, NeraCare, MSD Sharp and Dohme
OpenAlex ID: W3117348379
FWCI: 3.693
Cites: 110
Cited by: 268
Related to: 10
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Supporters
Legal
Privacy
Accessibility
Terms
Security